{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:11:36Z","timestamp":1781007096132,"version":"3.54.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.survophthal.2025.11.006","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:51:19Z","timestamp":1762361479000},"page":"1006-1009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Out of sight, hiding in plain clues"],"prefix":"10.1016","volume":"71","author":[{"given":"Laia","family":"Peraferrer-Montesinos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Susin-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose E.","family":"Mart\u00ednez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7685-4027","authenticated-orcid":false,"given":"Marta","family":"Saint-Gerons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.survophthal.2025.11.006_bib1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease. International MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.survophthal.2025.11.006_bib2","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/13524585251313744","article-title":"Testing for myelin oligodendrocyte glycoprotein antibodies: who, what, where, when, why, and how","volume":"31","author":"Budhram","year":"2025","journal-title":"Mult Scler"},{"issue":"11","key":"10.1016\/j.survophthal.2025.11.006_bib3","doi-asserted-by":"crossref","first-page":"e1095","DOI":"10.1212\/WNL.0000000000201662","article-title":"Significance of myelin oligodendrocyte glycoprotein antibodies in CSF: a retrospective multicenter study","volume":"100","author":"Carta","year":"2023","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.survophthal.2025.11.006_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/jhm.13097","article-title":"Clinical guideline highlights for the hospitalist: management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"18","author":"Chitnis","year":"2023","journal-title":"J Hosp Med"},{"issue":"1","key":"10.1016\/j.survophthal.2025.11.006_bib5","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/ana.25909","article-title":"Clinical features and risk of relapse in children and adults with myelin oligodendrocyte glycoprotein antibody- associated disease","volume":"89","author":"Cobo-Calvo","year":"2021","journal-title":"Ann Neurol"},{"key":"10.1016\/j.survophthal.2025.11.006_bib6","doi-asserted-by":"crossref","DOI":"10.1177\/13524585251336891","article-title":"Treatment discontinuation in MOGAD: a reassuring step forward","author":"Hacohen","year":"2025","journal-title":"Mult Scler"},{"issue":"12","key":"10.1016\/j.survophthal.2025.11.006_bib7","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1038\/s41433-024-03108-y","article-title":"MOG antibody-associated optic neuritis","volume":"38","author":"Jeyakumar","year":"2024","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.survophthal.2025.11.006_bib8","doi-asserted-by":"crossref","DOI":"10.1177\/13524585251320046","article-title":"Outcomes of immunosuppressive therapy discontinuation in patients with myelin oligodendrocyte glycoprotein antibody-associated disease","author":"Kang","year":"2025","journal-title":"Mult Scler"},{"key":"10.1016\/j.survophthal.2025.11.006_bib9","doi-asserted-by":"crossref","unstructured":"Kwon Y.N., Tisavipat N., Kim S.M.et al. Assessment of concurrent neoplasms and a paraneoplastic association in MOGAD. Ann Clin Transl Neurol. 2025 Apr;12(4):861-870Trentinaglia M, Dinoto A, Carta S, et al. Investigating the association between neoplasms and MOG antibody-associated disease. Front Neurol 2023; 14:1193211.","DOI":"10.3389\/fneur.2023.1193211"},{"key":"10.1016\/j.survophthal.2025.11.006_bib10","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1212\/WNL.0000000000200055","article-title":"MOG-IgG-associated demyelination induced by pembrolizumab treatment in a patient with malignant melanoma","volume":"98","author":"Liu","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.survophthal.2025.11.006_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200275","article-title":"MOG CNS autoimmunity and MOGAD","volume":"11","author":"Moseley","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"36","key":"10.1016\/j.survophthal.2025.11.006_bib12","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.survophthal.2025.11.006_bib13","first-page":"519","article-title":"Neuro-ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","volume":"41","author":"Sun","year":"2021","journal-title":"J NeuroOphthalmol J North Am NeuroOphthalmol Soc"},{"key":"10.1016\/j.survophthal.2025.11.006_bib14","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200249","article-title":"MOG antibody-associated disease in the setting of metastatic melanoma complicated by immune checkpoint inhibitor use","volume":"11","author":"Syc-Mazurek","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.survophthal.2025.11.006_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1193211","article-title":"Investigating the association between196 neoplasms and MOG antibody-associated disease","author":"Trentinaglia","year":"2023","journal-title":"Front Neurol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001997?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625725001997?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:56:51Z","timestamp":1781006211000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625725001997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0039625725001997"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.11.006","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Out of sight, hiding in plain clues","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2025.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}